美股异动丨诺和诺德夜盘拉升涨超2%，Q2明星减肥药Wegovy销售额超预期

Core Viewpoint - Novo Nordisk's Q2 earnings report showed mixed results, with revenue and net profit falling short of market expectations, while the sales of its weight loss drug Wegovy exceeded forecasts [1] Financial Performance - Q2 revenue was 76.86 billion Danish Krone, below the market estimate of 76.99 billion Danish Krone [1] - Net profit reached 26.5 billion Danish Krone, lower than the expected 27.01 billion Danish Krone [1] Product Sales - Total sales of GLP-1 drugs, including Ozempic and Wegovy, amounted to 38.37 billion Danish Krone, missing the forecast of 39.45 billion Danish Krone [1] - Wegovy, the key weight loss drug, generated sales of 19.53 billion Danish Krone, surpassing the market expectation of 19.2 billion Danish Krone [1] - Core diabetes and obesity care business sales totaled 71.94 billion Danish Krone, falling short of the anticipated 73.04 billion Danish Krone [1]